Literature DB >> 28083737

Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer.

Kei Tanaka1, Yoichi Kobayashi2, Juri Sugiyama3, Tatsuo Yamazaki4, Kei Dozono1, Momoe Watanabe1, Hiromi Shibuya1, Yoshiko Nishigaya1, Mai Momomura1, Hironori Matsumoto1, Satoshi Umezawa4, Kiyoshi Takamatsu3, Mitsutoshi Iwashita1.   

Abstract

BACKGROUND: Prognostic clinicopathological factors for type 1 endometrial cancer are unknown and the purpose of the current study was to determine the independent prognostic variables for type 1 endometrial cancer.
METHODS: We performed a retrospective study of 168 patients with type 1 endometrial cancer primarily treated with comprehensive staging surgery. The median follow-up time was 68 (12-100) months. Independent risk factors for disease-free survival (DFS) and overall survival (OS) were determined using multivariate Cox regression models. Sub-group analysis of stage I was also performed. We also assessed the patterns of failure among patients with recurrences and investigated the associations with the prognostic variables determined by multivariate analysis.
RESULTS: Twenty patients (11.9%) had recurrence and 13 patients (7.7%) died of the disease overall. Multivariate analysis revealed that grade 2 (G2) histology (p = 0.008) and positive peritoneal cytology (p = 0.001) predicted the recurrent event in type 1 endometrial cancer. G2 histology (p = 0.007) and positive peritoneal cytology (p = 0.003) were also found to be independent risk factors for tumor-related deaths. Among stage I patients, G2 histology and positive peritoneal cytology were also independent prognostic variables for DFS and OS. Patients with G2 histology and/or positive peritoneal cytology were more likely to have recurrence at distant sites.
CONCLUSIONS: G2 histology and positive peritoneal cytology were independent prognostic factors for DFS and OS in type 1 endometrial cancer.

Entities:  

Keywords:  Endometrial cancer; Peritoneal cytology; Prognostic factor; Tumor grade; Type1

Mesh:

Year:  2017        PMID: 28083737     DOI: 10.1007/s10147-016-1079-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  31 in total

1.  Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.

Authors:  Sergio Pecorelli
Journal:  Int J Gynaecol Obstet       Date:  2009-05       Impact factor: 3.561

2.  Predictability of retroperitoneal lymph node metastasis by using clinicopathologic variables in surgically staged endometrial cancer.

Authors:  C Taskiran; K Yuce; P O Geyik; T Kucukali; A Ayhan
Journal:  Int J Gynecol Cancer       Date:  2006 May-Jun       Impact factor: 3.437

Review 3.  Peritoneal cytology in endometrial carcinoma.

Authors:  G P Sutton
Journal:  Cancer Treat Res       Date:  1989

4.  The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.

Authors:  Laura J Havrilesky; Janiel M Cragun; Brian Calingaert; Angeles Alvarez Secord; Fidel A Valea; Daniel L Clarke-Pearson; Andrew Berchuck; John T Soper
Journal:  Gynecol Oncol       Date:  2006-10-02       Impact factor: 5.482

5.  Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure.

Authors:  Angiolo Gadducci; Stefania Cosio; Maria Grazia Fabrini; Antonio Fanucchi; Cecilia Barsotti; Renza Cristofani; Carlo Greco; Andrea Riccardo Genazzani
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

6.  Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk early-stage endometrioid endometrial cancer.

Authors:  Lori E Weinberg; Charles A Kunos; Kristine M Zanotti
Journal:  Int J Gynecol Cancer       Date:  2013-10       Impact factor: 3.437

7.  Endometrial adenocarcinoma in Norway. A study of a total population.

Authors:  V M Abeler; K E Kjørstad
Journal:  Cancer       Date:  1991-06-15       Impact factor: 6.860

8.  Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?

Authors:  Teresa Alvarez; Ezra Miller; Linda Duska; Esther Oliva
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

Review 9.  Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.

Authors:  D Llobet; J Pallares; A Yeramian; M Santacana; N Eritja; A Velasco; X Dolcet; X Matias-Guiu
Journal:  J Clin Pathol       Date:  2008-10-31       Impact factor: 3.411

10.  Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus.

Authors:  T Kasamatsu; T Onda; N Katsumata; M Sawada; T Yamada; R Tsunematsu; K Ohmi; Y Sasajima; Y Matsuno
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

View more
  3 in total

1.  Risk Factors and Prognosis of Early Recurrence in Stage I-II Endometrial Cancer: A Large-Scale, Multi-Center, and Retrospective Study.

Authors:  Yingyu Dou; Kun Song; Yu Fu; Yuanming Shen; Chuyao Zhang; Shuzhong Yao; Congjian Xu; Min Xia; Ge Lou; Jihong Liu; Bei Lin; Jianliu Wang; Weidong Zhao; Jieqing Zhang; Wenjun Cheng; Hongyan Guo; Ruixia Guo; Fengxia Xue; Xipeng Wang; Lili Han; Xia Zhao; Xiaomao Li; Ping Zhang; Jianguo Zhao; Jiezhi Ma; Wenting Li; Xiaohang Yang; Zizhuo Wang; Jingbo Liu; Yong Fang; Kezhen Li; Gang Chen; Chaoyang Sun; Xiaodong Cheng; Jie Jiang; Beibei Wang; Danfeng Luo; Beihua Kong
Journal:  Front Med (Lausanne)       Date:  2022-04-14

2.  An elevated preoperative serum calcium level is a significant predictor for positive peritoneal cytology in endometrial carcinoma.

Authors:  Xingchen Li; Yuan Cheng; Yangyang Dong; Boqiang Shen; Xiao Yang; Jiaqi Wang; Jingyi Zhou; Jianliu Wang
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

3.  Clinicopathological Characteristics and Prognosis in Endometrial Cancer With Bone Metastasis: A SEER-Based Study of 584 Women.

Authors:  Hejia Hu; Zhan Wang; Miaofeng Zhang; Feng Niu; Qunfei Yu; Ying Ren; Zhaoming Ye
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.